Supplementary Fig. S6 from Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
Year: 2023
Type: supplementary-materials
Abstract: Logistic regression model calibration. A, Model 1. B, Model 2. C, Model 3. D, Model 4. E, Model 5. F, Model 6. G, Model 7. A-G, Calibration curves with summary statistics. Dxy is the Somer's rank correlation between the predicted and observed values; C (ROC) is the area under the curve; R2 is the Nagelkerke-Cox-Snell-Maddala-Magee R-squared index; D is the discrimination index; U is the Unreliability index; Q is the Quality index; the Brier score is the average squared difference in the predicted and observed values; Emax is the maximum absolute difference in predicted and loess-calibrated probabili-ties; Eavg is the average absolute difference in predicted and loess-calibrated probabilities; E90 is the 0.9 quantile of the absolute difference in predicted and loess-calibrated probabilities; S:z and S:p are the Spiegelhalter Z-test for calibration accuracy and its two-tailed p-value.
Authors: Otto Metzger Filho, Giuseppe Viale, Shayna Stein, Lorenzo Trippa, Denise A. Yardley, Ingrid A. Mayer, Vandana G. Abramson, Carlos L. Arteaga, Laura M. Spring, Adrienne G. Waks, Eileen Wrabel, Michelle K. DeMeo, Aditya Bardia, Patrizia Dell'Orto, Leila Russo, Tari A. King, Kornelia Polyak, Franziska Michor, Eric P. Winer, Ian E. Krop
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362566676